Limits...
Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis.

Wang Y, Wang S, Xu S, Qu J, Liu B - PLoS ONE (2014)

Bottom Line: A significant lower EML4-ALK fusion gene positive rate was associated with smokers (pooled OR = 0.40, 95% CI = 0.30-0.54, P<0.00001).We found that a significantly lower EML4-ALK fusion gene positivity rate was associated with EGFR mutation (pooled OR = 0.07, 95% CI = 0.03-0.19, P<0.00001).No publication bias was observed in any meta-analysis (all P value of Egger's test >0.05); however, because of the small sample size, no results were in the meta-analysis regarding EGFR gene status.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Shenyang Medical College, Shenyang, Liaoning, People's Republic of China.

ABSTRACT

Background: The frequencies of EML4-ALK fusion gene in non-small cell lung cancer (NSCLC) with different clinicopathologic features described by previous studies are inconsistent. The key demographic and pathologic features associated with EML4-ALK fusion gene have not been definitively established. This meta-analysis was conducted to compare the frequency of the EML4-ALK fusion gene in patients with different clinicopathologic features and to identify an enriched population of patients with NSCLC harboring EML4-ALK fusion gene.

Methods: The Pubmed and Embase databases for all studies on EML4-ALK fusion gene in NSCLC patients were searched up to July 2014. A criteria list and exclusion criteria were established to screen the studies. The frequency of the EML4-ALK fusion gene and the clinicopathologic features, including smoking status, pathologic type, gender, and EGFR status were abstracted.

Results: Seventeen articles consisting of 4511 NSCLC cases were included in this meta-analysis. A significant lower EML4-ALK fusion gene positive rate was associated with smokers (pooled OR = 0.40, 95% CI = 0.30-0.54, P<0.00001). A significantly higher EML4-ALK fusion gene positivity rate was associated with adenocarcinomas (pooled OR = 2.53, 95% CI = 1.66-3.86, P<0.0001) and female (pooled OR = 0.61, 95% CI = 0.41-0.90, P = 0.01). We found that a significantly lower EML4-ALK fusion gene positivity rate was associated with EGFR mutation (pooled OR = 0.07, 95% CI = 0.03-0.19, P<0.00001). No publication bias was observed in any meta-analysis (all P value of Egger's test >0.05); however, because of the small sample size, no results were in the meta-analysis regarding EGFR gene status.

Conclusion: This meta-analysis revealed that the EML4-ALK fusion gene is highly correlated with a never/light smoking history, female and the pathologic type of adenocarcinoma, and is largely mutually exclusive of EGFR.

Show MeSH

Related in: MedlinePlus

Forest plots of studies with an association between the EML4-ALK fusion gene and gender.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4215846&req=5

pone-0110617-g004: Forest plots of studies with an association between the EML4-ALK fusion gene and gender.

Mentions: Gender information was available for 16 studies, and included a total of 2265 male and 1682 female patients. EML4-ALK was detected in 118 (4.82%) males and 135 (7.64%) females. The results of this meta-analysis are shown in Fig. 4. Overall, when all of the eligible studies were pooled into the meta-analysis, significant heterogeneity was observed (I2 = 45%, P = 0.03), thus the random-effects model was chosen. EML4-ALK mutant tumors were more likely to be women (pooled OR = 0.61, 95% CI = 0.41–0.90, P = 0.01).


Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis.

Wang Y, Wang S, Xu S, Qu J, Liu B - PLoS ONE (2014)

Forest plots of studies with an association between the EML4-ALK fusion gene and gender.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4215846&req=5

pone-0110617-g004: Forest plots of studies with an association between the EML4-ALK fusion gene and gender.
Mentions: Gender information was available for 16 studies, and included a total of 2265 male and 1682 female patients. EML4-ALK was detected in 118 (4.82%) males and 135 (7.64%) females. The results of this meta-analysis are shown in Fig. 4. Overall, when all of the eligible studies were pooled into the meta-analysis, significant heterogeneity was observed (I2 = 45%, P = 0.03), thus the random-effects model was chosen. EML4-ALK mutant tumors were more likely to be women (pooled OR = 0.61, 95% CI = 0.41–0.90, P = 0.01).

Bottom Line: A significant lower EML4-ALK fusion gene positive rate was associated with smokers (pooled OR = 0.40, 95% CI = 0.30-0.54, P<0.00001).We found that a significantly lower EML4-ALK fusion gene positivity rate was associated with EGFR mutation (pooled OR = 0.07, 95% CI = 0.03-0.19, P<0.00001).No publication bias was observed in any meta-analysis (all P value of Egger's test >0.05); however, because of the small sample size, no results were in the meta-analysis regarding EGFR gene status.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Shenyang Medical College, Shenyang, Liaoning, People's Republic of China.

ABSTRACT

Background: The frequencies of EML4-ALK fusion gene in non-small cell lung cancer (NSCLC) with different clinicopathologic features described by previous studies are inconsistent. The key demographic and pathologic features associated with EML4-ALK fusion gene have not been definitively established. This meta-analysis was conducted to compare the frequency of the EML4-ALK fusion gene in patients with different clinicopathologic features and to identify an enriched population of patients with NSCLC harboring EML4-ALK fusion gene.

Methods: The Pubmed and Embase databases for all studies on EML4-ALK fusion gene in NSCLC patients were searched up to July 2014. A criteria list and exclusion criteria were established to screen the studies. The frequency of the EML4-ALK fusion gene and the clinicopathologic features, including smoking status, pathologic type, gender, and EGFR status were abstracted.

Results: Seventeen articles consisting of 4511 NSCLC cases were included in this meta-analysis. A significant lower EML4-ALK fusion gene positive rate was associated with smokers (pooled OR = 0.40, 95% CI = 0.30-0.54, P<0.00001). A significantly higher EML4-ALK fusion gene positivity rate was associated with adenocarcinomas (pooled OR = 2.53, 95% CI = 1.66-3.86, P<0.0001) and female (pooled OR = 0.61, 95% CI = 0.41-0.90, P = 0.01). We found that a significantly lower EML4-ALK fusion gene positivity rate was associated with EGFR mutation (pooled OR = 0.07, 95% CI = 0.03-0.19, P<0.00001). No publication bias was observed in any meta-analysis (all P value of Egger's test >0.05); however, because of the small sample size, no results were in the meta-analysis regarding EGFR gene status.

Conclusion: This meta-analysis revealed that the EML4-ALK fusion gene is highly correlated with a never/light smoking history, female and the pathologic type of adenocarcinoma, and is largely mutually exclusive of EGFR.

Show MeSH
Related in: MedlinePlus